SRR10900019
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.400
- ESTROGEN_RESPONSE_LATE+0.400
- INFLAMMATORY_RESPONSE+0.400
- ALLOGRAFT_REJECTION+0.300
- ANGIOGENESIS+0.300
- APICAL_JUNCTION+0.300
- APICAL_SURFACE+0.300
- COMPLEMENT+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
Top 10 suppressed
- MYC_TARGETS_V1-0.600
- MYC_TARGETS_V2-0.500
- OXIDATIVE_PHOSPHORYLATION-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.400
- DNA_REPAIR-0.300
- E2F_TARGETS-0.300
- PROTEIN_SECRETION-0.300
- G2M_CHECKPOINT-0.200
- MTORC1_SIGNALING-0.200
- SPERMATOGENESIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10899987 | — | — | 0.902 |
| 2 | s0102868 | — | — | 0.886 |
| 3 | TCGA-22-1000-01A-01R-A32Z-07 | — | cohortSQ1 | 0.886 |
| 4 | SRR1465632 | GTEX | — | 0.870 |
| 5 | a802b49c.736d.427c.bcca.8375c4171284 | — | cohortA1 | 0.868 |
| 6 | BS_TA9WP4TH | Med | Medulloblastoma | 0.867 |
| 7 | SRR17866847 | — | — | 0.865 |
| 8 | SRR1093773 | GTEX | — | 0.863 |
| 9 | SRR1440082 | GTEX | — | 0.862 |
| 10 | TCGA-A2-A0YD-01A-11R-A109-07 | — | A | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.400 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |